MEP16408A - Combination of a taxane and a cyclin-dependent kinase inhibitor - Google Patents

Combination of a taxane and a cyclin-dependent kinase inhibitor

Info

Publication number
MEP16408A
MEP16408A MEP-164/08A MEP16408A MEP16408A ME P16408 A MEP16408 A ME P16408A ME P16408 A MEP16408 A ME P16408A ME P16408 A MEP16408 A ME P16408A
Authority
ME
Montenegro
Prior art keywords
cyclin
dependent kinase
taxane
combination
kinase inhibitor
Prior art date
Application number
MEP-164/08A
Other languages
English (en)
Croatian (hr)
Inventor
Marie-Christi Ne Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP16408A publication Critical patent/MEP16408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Opisana je farmaceutska kompozicija koja ukljućuje Taxol®, Taxoter® ili derivati i ciklinzavisnu kinazu, kao i način primjene, pri čemu se taxn daje naizmjenično, a ciklin-zavisna kinaza se daje sa ponavljanjem u okviru istog ciklusa.
MEP-164/08A 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor MEP16408A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (1)

Publication Number Publication Date
MEP16408A true MEP16408A (en) 2010-10-10

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-164/08A MEP16408A (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Country Status (33)

Country Link
US (2) US20020182204A1 (bs)
EP (1) EP1372652B1 (bs)
JP (1) JP2004521140A (bs)
KR (1) KR100879712B1 (bs)
CN (1) CN1498107A (bs)
AR (1) AR034222A1 (bs)
AT (1) ATE395917T1 (bs)
AU (1) AU2002312815B2 (bs)
BR (1) BR0208221A (bs)
CA (1) CA2441441C (bs)
CY (1) CY1110449T1 (bs)
CZ (1) CZ301423B6 (bs)
DE (1) DE60226710D1 (bs)
DK (1) DK1372652T3 (bs)
EA (1) EA007815B1 (bs)
ES (1) ES2305253T3 (bs)
HR (1) HRPK20030766B3 (bs)
HU (1) HU229258B1 (bs)
IL (2) IL158058A0 (bs)
ME (1) MEP16408A (bs)
MX (1) MXPA03007743A (bs)
NO (1) NO332441B1 (bs)
NZ (1) NZ527655A (bs)
PE (1) PE20020907A1 (bs)
PL (1) PL206118B1 (bs)
PT (1) PT1372652E (bs)
RS (1) RS50681B (bs)
SI (1) SI1372652T1 (bs)
SK (1) SK287481B6 (bs)
TW (1) TWI355935B (bs)
UY (1) UY27220A1 (bs)
WO (1) WO2002076484A2 (bs)
ZA (1) ZA200307381B (bs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
WO2004035034A2 (en) * 2002-10-16 2004-04-29 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
WO2007090794A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
MX2013005661A (es) * 2010-11-19 2013-09-13 Piramal Entpr Ltd Combinacion farmaceutica de paclitaxel y un inhibidor cdk (quinasa dependiente de ciclina).
SI2694056T1 (sl) * 2011-04-01 2019-12-31 Astrazeneca Ab Terapevtsko zdravljenje
PL2785349T5 (pl) 2011-11-30 2023-01-30 Astrazeneca Ab Kombinacja do leczenia nowotworu
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0888458A4 (en) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PROTEIN KINASE C INHIBITORS AND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
AU2002312815B2 (en) 2006-08-24
CA2441441C (en) 2009-05-26
HRPK20030766B3 (en) 2006-11-30
CZ20032551A3 (en) 2004-07-14
JP2004521140A (ja) 2004-07-15
DK1372652T3 (da) 2008-09-22
HUP0303589A2 (hu) 2004-03-01
PT1372652E (pt) 2008-07-24
RS50681B (sr) 2010-06-30
NZ527655A (en) 2006-03-31
PE20020907A1 (es) 2002-12-19
NO20034124L (no) 2003-09-16
HU229258B1 (en) 2013-10-28
MXPA03007743A (es) 2004-11-12
EP1372652A2 (en) 2004-01-02
NO20034124D0 (no) 2003-09-16
HRP20030766A2 (en) 2005-06-30
CZ301423B6 (cs) 2010-02-24
IL158058A0 (en) 2004-03-28
WO2002076484A2 (en) 2002-10-03
PL367702A1 (en) 2005-03-07
SK11692003A3 (sk) 2004-03-02
ATE395917T1 (de) 2008-06-15
WO2002076484A3 (en) 2003-01-03
TWI355935B (en) 2012-01-11
CN1498107A (zh) 2004-05-19
KR100879712B1 (ko) 2009-01-22
EP1372652B1 (en) 2008-05-21
HUP0303589A3 (en) 2007-05-02
IL158058A (en) 2010-02-17
ZA200307381B (en) 2005-03-30
YU69503A (sh) 2006-08-17
SK287481B6 (sk) 2010-11-08
US20060128640A1 (en) 2006-06-15
ES2305253T3 (es) 2008-11-01
CY1110449T1 (el) 2015-04-29
AR034222A1 (es) 2004-02-04
DE60226710D1 (de) 2008-07-03
UY27220A1 (es) 2002-09-30
BR0208221A (pt) 2004-03-02
US20020182204A1 (en) 2002-12-05
EA007815B1 (ru) 2007-02-27
SI1372652T1 (sl) 2008-10-31
CA2441441A1 (en) 2002-10-03
EA200301053A1 (ru) 2004-02-26
PL206118B1 (pl) 2010-07-30
NO332441B1 (no) 2012-09-17
KR20030086318A (ko) 2003-11-07

Similar Documents

Publication Publication Date Title
HN2002000300A (es) Nuevos derivados de piperazina
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
BRPI0414539B8 (pt) composto, composição farmacêutica, e, uso de um composto
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
AR063555A1 (es) Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos
AR030857A1 (es) Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
HN2001000235A (es) Derivados puentes de piperazina
AR029509A1 (es) Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales
BR0208566B1 (pt) Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
UY27133A1 (es) 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)
UY27376A1 (es) Formulación de medicamento que contiene un antagonista de ltb4
ECSP045086A (es) Composiciones farmaceuticas que contienen macrolidos
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
FR2797446B1 (fr) Derives de phenanthroline-7-ones et leurs applications en therapeutique